Company Focus
Vertex Pharmaceuticals
Latest Vertex Pharmaceuticals News
Biotechnology
Rare disease drug pricing has long rested on a simple trade-off. Small patient populations and high development costs justified higher prices, and payers largely accepted that logic because the overall budget impact remained limited. That balance is becoming harder to maintain as orphan drugs now account for a growing share of new launches and an increasing portion of drug spending. 8 April 2026
Related News
Insights
Company Spotlight
A pharmaceutical company, based in USA, focused on developing rare diseases and hepatological therapeutics targeting significant areas of unmet medical need.
Latest News & Features of interest to Vertex Pharmaceuticals
Biotechnology
Enodia Therapeutics, a privately-held French biotech developing small molecule therapies targeting a unique form of protein degradation at the point of synthesis, has appointed Yvonne McGrath as chief scientific officer (CSO). 15 April 2026
Biotechnology
US clinical-stage biotechnology company Beeline Medicines today announced its official debut with the mission of developing and delivering category-leading precision therapies to transform the lives of people with autoimmune and inflammatory diseases. 15 April 2026
Biotechnology
French immunotherapy company OSE Immunotherapeutics provided a senior management update. 15 April 2026
Pharmaceutical
The local unit of US biotech major Biogen today announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization to the high dose regimen (50/28mg) of Spinraza (nusinersen) for the treatment of 5q spinal muscular atrophy (SMA). 14 April 2026
Pharmaceutical
US biopharma Travere Therapeutics has announced that the US Food and Drug Administration (FDA) has approved Filspari (sparsentan) to reduce proteinuria in adult and pediatric patients aged eight years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. 14 April 2026
Pharmaceutical
Novo Nordisk has announced a strategic partnership with OpenAI, the US AI research and deployment company. 14 April 2026
Generics
India’s generics industry appears to be reshaping the weight loss and diabetes drug market, with Eli Lilly’s share in the GLP-1 category slipping sharply in March. 14 April 2026
Generics
The Russian drugmaker Binnopharm Group, which was founded by the local billionaire Vladimir Yevtushenkov, hopes to acquire Akrikhin, the local drugmaker, which is owned by the Polish-Dutch company Polpharma and which produces some important and best selling drugs in the Russian market. 14 April 2026
Biotechnology
US biotech major Regeneron Pharmaceuticals and Australian radiopharmaceuticals specialist Telix Pharmaceuticals have announced a collaboration, sending the latter company’s shares up by 8% in Monday’s trading. 13 April 2026
Generics
The Russian Ministry of Health has begun more active cancelling of tenders for drug procurements, waiting for the launch of cheaper generics, as the federal budget experiences a shortage of funds for procurements of expensive original drugs. 13 April 2026
Latest In Brief for Vertex Pharmaceuticals
Biotechnology
US Biotech company Regenxbio and the University of Pennsylvania on Friday convinced a US appeals court to revive their patent lawsuit against Sarepta Therapeutics over Sarepta's Duchenne muscular dystrophy (DMD) treatment, according to a Reuters report. 23 February 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze